Sponsor or institution

Clinical trials and research at Gilead Sciences

• 28Clinical trials
• 43Countries

Newest trials

All recruiting trials (28)

• Weekly long-acting HIV-1 meds switch for people with undetectable virus

  This study tests whether switching to weekly oral long-acting HIV medicines works as well as staying on current daily pills for people with HIV who already have an undetectable viral load.

  Recruiting at 2 sites Phase 2 Gilead Sciences · Ft. Pierce, Florida and 1 other locations · NCT07841990

• Seladelpar and Cilofexor in Primary Biliary Cholangitis (PBC)

  This study tests whether combining seladelpar with cilofexor helps people with primary biliary cholangitis more than seladelpar alone or placebo.

  Recruiting at 4 sites Phase 2 Gilead Sciences · Colorado Springs, Colorado and 3 other locations · NCT07841977

• TUB-040 with standard ovarian cancer drugs in high-grade ovarian cancer

  This study tests whether adding TUB-040 to standard ovarian cancer treatments is safe and shows early signs it can help people with high-grade ovarian cancer that responded to platinum therapy.

  Recruiting at 7 sites Phase 1/2 Gilead Sciences · Los Angeles, California and 7 other locations · NCT07736937

• GS-0415 safety and PK in people with HIV on ART

  This study tests GS-0415 in adults with HIV who are on stable ART to see if it is safe, tolerable, and how the drug behaves in the body.

  Recruiting at 15 sites Phase 1 Gilead Sciences · Los Angeles, California and 15 other locations · NCT07719491

• Gilead study of GS-3242 with Lenacapavir for people starting HIV treatment compared with Biktarvy

  This study tests whether injecting GS-3242 with Lenacapavir can work as well as Biktarvy for people newly starting HIV treatment.

  Recruiting at 19 sites Phase 2/3 Gilead Sciences · Torrance, California and 20 other locations · NCT07708727

• GS-1206 in adults with solid tumors

  This study tests GS-1206 in adults with solid tumors to see if it is safe and has anti-tumor activity.

  Recruiting at 4 sites Phase 1 Gilead Sciences · Grand Rapids, Michigan and 3 other locations · NCT07703878

• Long-acting LEN/TAB/ZAB regimen vs daily HIV meds in adults with suppressed HIV-1

  This study tests whether switching to an injectable, long-acting combination (lenacapavir, teropavimab, zinlirvimab) can keep HIV-1 under control in adults who are already virally suppressed on stable oral therapy.

  Recruiting at 2 sites Phase 3 Gilead Sciences · Berkeley, Michigan and 1 other locations · NCT07683000

• Long-acting LEN/TAB/ZAB vs CAB/RPV in adults with HIV-1 who are virologically suppressed on daily ART

  This study tests whether switching to a weekly-plus long-acting injectable regimen of lenacapavir, teropavimab, and zinlirvimab works as well as a two-drug injectable regimen of cabotegravir and rilpivirine for adults with HIV-1 who already have undetectable virus on daily treatment.

  Recruiting at 19 sites Phase 3 Gilead Sciences · San Francisco, California and 18 other locations · NCT07682961

• Switch to GS-3242 plus Lenacapavir vs Biktarvy in virologically suppressed people with HIV-1

  This study tests whether switching to GS-3242 with Lenacapavir can maintain viral suppression better than staying on Biktarvy in people living with HIV-1 who are already suppressed.

  Recruiting at 51 sites Phase 2 Gilead Sciences · Phoenix, Arizona and 58 other locations · NCT07645287

• GS-2426 in MTAP-deleted advanced solid tumors

  This study tests whether GS-2426 is safe and tolerable in adults with MTAP-deleted advanced solid tumors to help find a suitable dose for further testing.

  Recruiting at 6 sites Phase 1 Gilead Sciences · Boston, Massachusetts and 5 other locations · NCT07601243

• Denikitug (GS-1811) given alone or with nivolumab or with chemotherapy for advanced colorectal cancer

  This study tests Denikitug alone and in combination with nivolumab or with chemotherapy for adults whose colorectal cancer is advanced and MSS.

  Recruiting at 8 sites Phase 2 Gilead Sciences · North Haven, Connecticut and 14 other locations · NCT07527858

• Lenacapavir (YEZTUGO) as an HIV PrEP option in routine clinical care

  This project will see if using lenacapavir (YEZTUGO) as a PrEP option helps people at risk for HIV stay on prevention over one year in U.S. clinics.

  Recruiting at 44 sites Gilead Sciences · Birmingham, Alabama and 43 other locations · NCT07473778

• KITE-363 treatment for relapsed or refractory autoimmune neurologic diseases

  This study will test whether KITE-363 is safe and can help people with relapsed or treatment-resistant autoimmune neurologic diseases such as MS, CIDP, and myasthenia gravis.

  Recruiting at 10 sites Phase 1 Gilead Sciences · Newport Beach, California and 9 other locations · NCT07304154

• GS-5319 for adults with MTAP-deficient advanced solid tumors

  This trial will test GS-5319 to find a safe dose and see if it is tolerated by adults whose advanced solid tumors lack the MTAP gene.

  Recruiting at 12 sites Phase 1 Gilead Sciences · Boston, Massachusetts and 11 other locations · NCT07128303

• GS-4321 for healthy volunteers and people with chronic hepatitis delta

  This study tries to find safe doses of GS-4321 in healthy volunteers and see if the drug is safe and can lower hepatitis delta virus levels in people with chronic hepatitis delta.

  Recruiting at 28 sites Phase 1/2 Gilead Sciences · Anaheim, California and 27 other locations · NCT07096193

• Testing a new dosing schedule of sacituzumab govitecan for advanced triple-negative breast cancer

  This study is testing a new way to give a cancer drug called sacituzumab govitecan to see if it is safe and effective for people with advanced triple-negative breast cancer.

  Recruiting at 15 sites Phase 1/2 Gilead Sciences · Los Angeles, California and 15 other locations · NCT06926920

• Comparing sacituzumab govitecan to standard care for advanced small cell lung cancer

  This study is testing whether a new treatment called sacituzumab govitecan can help people with advanced small cell lung cancer live longer and feel better compared to standard care.

  Recruiting at 206 sites Phase 3 Gilead Sciences · Anchorage, Alaska and 218 other locations · NCT06801834

• Long-acting Lenacapavir for treating HIV-1 in adolescents and children

  This study is testing a new long-acting HIV treatment called lenacapavir to see if it works better for adolescents and children who have had problems with their current medications.

  Recruiting at 8 sites Phase 2 Gilead Sciences · Atlanta, Georgia and 8 other locations · NCT06749054

• Testing TUB-030 for advanced solid tumors

  This study is testing a new drug called TUB-030 to see if it can safely help adults with advanced solid tumors, especially those with head and neck cancer or non-small cell lung cancer.

  Recruiting at 19 sites Phase 1/2 Gilead Sciences · New Haven, Connecticut and 19 other locations · NCT06657222

• Treatment of generalized myasthenia gravis with a new CAR-T therapy

  This study is testing a new CAR-T therapy to see if it can safely help adults with generalized myasthenia gravis feel better.

  Recruiting at 14 sites Phase 1 Gilead Sciences · Los Angeles, California and 13 other locations · NCT06626919

• Evaluating GS-4571 in Healthy and Obese Participants with Type 2 Diabetes

  This study is testing a new drug called GS-4571 in healthy people and those with obesity or Type 2 diabetes to see how safe it is and how the body processes it.

  Recruiting at 3 sites Phase 1 Gilead Sciences · Miami, Florida and 2 other locations · NCT06562907

• Testing GS-2121 alone or with zimberelimab in adults with advanced solid tumors

  This study is testing a new treatment called GS-2121, alone and with another drug called zimberelimab, to see how safe it is for adults with advanced solid tumors.

  Recruiting at 6 sites Phase 1 Gilead Sciences · Palo Alto, California and 5 other locations · NCT06532565

• Providing ongoing access to HIV treatment for children and adolescents

  This study is testing whether children and teens with HIV can keep getting their treatment or switch to a new combination therapy to ensure they stay healthy.

  Recruiting at 13 sites Phase 4 Gilead Sciences · Buenos Aires and 16 other locations · NCT06337032

• Investigating a new treatment for ovarian and lung cancer patients

  This study is testing a new drug called TUB-040 to see if it can safely help people with ovarian and lung cancer feel better.

  Recruiting at 19 sites Phase 1/2 Gilead Sciences · Birmingham, Alabama and 20 other locations · NCT06303505

• Testing GS-0201 alone and with another drug in patients with advanced solid tumors

  This study is testing a new drug called GS-0201, alone and with another drug, to see if it’s safe and how much of it can be given to people with advanced solid tumors.

  Recruiting at 8 sites Phase 1 Gilead Sciences · Boston, Massachusetts and 7 other locations · NCT06167317

• Evaluating Seladelpar for Primary Biliary Cholangitis with Cirrhosis

  This study is testing if a new medication called Seladelpar can help adults with Primary Biliary Cholangitis and cirrhosis feel better and improve their liver health.

  Recruiting at 215 sites Phase 3 Gilead Sciences · Birmingham, Alabama and 217 other locations · NCT06051617

• Combination treatment for triple negative breast cancer after surgery

  This study is testing if a new combination of two cancer drugs can help adults with triple negative breast cancer who still have cancer after surgery feel better and live longer.

  Recruiting at 290 sites Phase 3 Gilead Sciences · Birmingham, Alabama and 377 other locations · NCT05633654

• Evaluating sacituzumab govitecan for advanced solid tumors in patients with liver impairment

  This study is testing a new cancer treatment called sacituzumab govitecan to see if it's safe and effective for people with advanced tumors who also have liver problems.

  Recruiting at 13 sites Phase 1 Gilead Sciences · Long Beach, California and 14 other locations · NCT04617522

Quick answers

How many clinical trials run by Gilead Sciences are recruiting right now?

28, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 43 countries. The most sites are in United States (27 trials), Spain (10 trials), Australia (8 trials), Canada (7 trials), South Korea (7 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1: 10, Phase 2: 5, Phase 1/2: 5, Phase 3: 5. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →